Recro Pharma Inc (REPH) Receives Average Recommendation of “Buy” from Analysts

Recro Pharma Inc (NASDAQ:REPH) has been given a consensus rating of “Buy” by the seven brokerages that are covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.21.

A number of brokerages have issued reports on REPH. Roth Capital set a $20.00 price objective on Recro Pharma and gave the company a “buy” rating in a report on Saturday, May 13th. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Wednesday, May 17th. Finally, Aegis reissued a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a report on Monday, March 27th.

In related news, major shareholder Stonepine Capital Management, sold 510,000 shares of Recro Pharma stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $7.40, for a total value of $3,774,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Scp Vitalife Partners Ii Lp sold 44,977 shares of Recro Pharma stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $8.00, for a total value of $359,816.00. Following the completion of the transaction, the insider now directly owns 2,276,571 shares of the company’s stock, valued at $18,212,568. The disclosure for this sale can be found here. Insiders sold 1,016,914 shares of company stock valued at $7,678,499 over the last ninety days. 39.30% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC boosted its position in Recro Pharma by 17.8% in the first quarter. Janney Montgomery Scott LLC now owns 12,485 shares of the specialty pharmaceutical company’s stock worth $109,000 after buying an additional 1,885 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Recro Pharma during the fourth quarter worth about $118,000. Acadian Asset Management LLC acquired a new position in Recro Pharma during the first quarter worth about $150,000. Wells Fargo & Company MN boosted its position in Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 500 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Recro Pharma during the first quarter worth about $156,000. 53.23% of the stock is owned by institutional investors and hedge funds.

Recro Pharma (NASDAQ REPH) traded down 3.43% during mid-day trading on Tuesday, hitting $7.32. 56,644 shares of the company were exchanged. Recro Pharma has a 12-month low of $5.89 and a 12-month high of $12.50. The company’s market cap is $139.45 million. The stock’s 50 day moving average is $7.95 and its 200-day moving average is $7.79.

Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.15. The company had revenue of $18.74 million during the quarter, compared to analysts’ expectations of $15.58 million. Recro Pharma had a negative return on equity of 57.17% and a negative net margin of 13.34%. Equities research analysts predict that Recro Pharma will post ($2.35) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Mideast Time and is owned by of Mideast Time. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.mideasttime.com/recro-pharma-inc-reph-receives-average-recommendation-of-buy-from-analysts-2/1756682.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:REPH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.